| Detected | Trial | Change |
|---|---|---|
| 2026-05-29 | NCT07427394 Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With… |
Recruitment opened |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05774951 | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of… | Breast Cancer, Early Breast Cancer | Recruiting |
| NCT06380751 | Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine… | Advanced Breast Cancer | Recruiting |
| NCT05952557 | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early… | Breast Cancer, Early Breast Cancer | Recruiting |
| NCT04964934 | Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m… | ER-Positive HER2-Negative Breast Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT07427394 | Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With… | Advanced Breast Cancer | Recruiting |
| NCT07195227 | Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer | Hormon Receptor Positive Breast Cancer | Recruiting |
| Phase 1/2 | |||
| NCT06188520 | A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and… | ER+ HER2- Advanced Breast Cancer | Recruiting |
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients… | Ovarian Cancer | Active, Not Recruiting |
| Phase 1 | |||
| NCT03616587 | Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. | ER+ HER2- Advanced Breast Cancer | Active, Not Recruiting |